Early Detection of PDAC in Patients With Chronic Pancreatitis

July 29, 2025 updated by: First Affiliated Hospital Xi'an Jiaotong University

High Efficiency of Early Detection of Synchronous Pancreatic Ductal Adenocarcinoma in Patients With Chronic Pancreatitis

The goal of this study is to find simple warning signs that doctors can use to spot pancreatic cancer early in people who have chronic pancreatitis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

359

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • The First Affiliated Hospital of Xi'an Jiaotong University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with CP upon admission to the First Affiliated Hospital of Xi'an Jiaotong University between January 2013 and December 2023

Description

Inclusion Criteria:

  1. a confirmed diagnosis of chronic pancreatitis; (2) availability of pathological confirmation.

Exclusion Criteria:

  1. age less than 18 years; (2) ambiguous pathology, including cases with only cytological findings or indications of pancreatic tissue alone; (3) preoperative diagnosis of PDAC or other pancreatic tumors before invasive procedure; (4) presence of tumors in other organs; (5) patients with missing data exceeding 15% of the total dataset.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
pathological diagnosis of PDAC
Time Frame: January 2013 and December 2023
January 2013 and December 2023

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2024

Primary Completion (Actual)

December 1, 2024

Study Completion (Actual)

December 1, 2024

Study Registration Dates

First Submitted

July 29, 2025

First Submitted That Met QC Criteria

July 29, 2025

First Posted (Actual)

August 5, 2025

Study Record Updates

Last Update Posted (Actual)

August 5, 2025

Last Update Submitted That Met QC Criteria

July 29, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ZXIITYFY2024202

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pancreatitis

Clinical Trials on histopathological confirmation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe